Ratings by Goldman Sachs (Kevin Strang)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/10/2026 | Stoke Therapeutics | STOK | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2026 | Praxis Precision Medicines Inc. | PRAX | Maintain | Buy (N/A) |
|
Details | ||
| 7/13/2026 | Stoke Therapeutics | STOK | New Coverage | Buy (N/A) |
31.38 (24.17) |
-22.98% | Details | |
| 7/13/2026 | Erasca Inc | ERAS | New Coverage | Early-Stage Biotech (N/A) |
18.53 (13.39) |
-27.74% | Details | |
| 7/13/2026 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Buy (N/A) |
324.99 (241.76) |
-25.61% | Details |
